Bio-Sourcing, a pioneering Belgian biotech firm, has secured total funding of €12.5 million to develop sustainable biotherapeutics. The funding comes from a mix of grants and equity to advance their innovative BioMilk platform.
With €2.5 million in grants and €10 million in equity, Bio-Sourcing aims to revolutionise the production of biosimilars using goat milk. This support underscores the potential of biotherapeutics in modern healthcare.
The €2.5 million grant will facilitate the clinical trials of Bio-Sourcing’s first biosimilar by 2027. In addition, €10 million in equity will fuel these trials and scale the company’s premises. The expansion plan includes upgrading the goat facility and constructing a milk processing plant, crucial for their operations.
Future biosimilars like trastuzumab and golimumab are in the pipeline, targeting common autoimmune conditions. The company aims to enhance accessibility to these essential drugs.
The company’s unique approach not only cuts costs but also positions them at the forefront of innovation. Bio-Sourcing envisions setting new industry standards with their pioneering platform.
Amid recent global health crises, the importance of localized biopharmaceutical production becomes clearer. Bio-Sourcing stands as a beacon of Europe’s efforts towards pharmaceutical self-sufficiency, crucial for future healthcare resilience.
Dr. Bertrand Merot, Bio-Sourcing’s CEO, expressed confidence in their platform as a transformative force for healthcare. “Our BioMilk platform is pivotal for making biotherapeutics more accessible,” he stated.
Bio-Sourcing’s developments promise a shift in the production paradigm, contributing to both economic and health sectors globally.
Bio-Sourcing’s success marks a critical step forward in sustainable biopharmaceutical production. The company’s forward-thinking approach not only addresses current industry challenges but also paves the way for future innovation.
Bio-Sourcing’s groundbreaking work in biotherapeutics presents a promising future for the industry. Through financial backing and strategic innovation, they are set to redefine access to essential healthcare solutions.
The funding boost from the EIC positions Bio-Sourcing as a leading force in biopharmaceuticals, with significant implications for sustainable healthcare production.
